Overview

Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus

Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective: Evaluate the efficacy and safety of daptomycin given for treatment of catheter-related bloodstream infections due to S. aureus bacteria with or without exchange of the central venous catheter (CVC) over guide wire in comparison with a historical control group of catheter-related S. aureus bacteremia treated with standard therapy (Vancomycin) or other active agents against staph aureus (such as beta-lactam antibiotics).
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Cubist Pharmaceuticals LLC
Treatments:
Daptomycin